Dr Sander Van Deventer | Chief Scientific Officer And General Manager

Dr Sander Van Deventer, Chief Scientific Officer And General Manager, uniQure

Dr. Sander van Deventer joined uniQure as Chief Scientific Officer, General Manager, Amsterdam in August, 2017.  Dr. van Deventer was a co-founder of uniQure's predecessor Amsterdam Molecular Therapeutics (AMT) in 1998 and Board member since 2010.  Dr. van Deventer is currently Operating Partner at Forbion Capital partners and Professor of Translational Gastroenterology at Leiden University Medical Center. He also currently serves as member of the Board for Argos Therapeutics (Durham, USA), Hookipa (Vienna, Austria), Staten Biotechnology (Naarden, The Netherlands) and enGene (Montreal, Canada). Dr. van Deventer is a trained internist and board-certified gastroenterologist. He received a Ph.D. from the University of Amsterdam, and became Director of the Laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam in 1995.


Day 1, Nov 7 @ 09:30

Keynote discussion: Executive industry insights - Why are we pursuing the same diseases?

  • What is it that companies need in order explore a new orphan indication or therapy area?
  • How to approach developing and launching treatments in as-yet untreated diseases that are not well-characterized
  • Insights into individual pipelines – what have we learnt that will make orphan drug research and development sustainable?

Day 1, Nov 7 @ 16:35

Overview of current gene therapies in the market: What are we working on?

  • Creating pipelines that are robust enough for gene therapy to become a reality
  • Preparing for later stage trials
last published: 17/Oct/18 12:05 GMT

back to speakers

Follow us on


Sign Up for Event Updates

Get Involved At World Orphan Drug Congress 2018


To Sponsor Or Exhibit


Andrew Mears
t/ +44 20 7092 1228


To Speak


Wing-Yun Cheung
t/ +44 20 7092 1172


To Register


Issa Mauthoor
t/ +44 20 7092 1257